Chain Drug Review
Investor Due Diligence Report
ghostHealth
CDR: Chain Drug Review
Investor Due Diligence Report
CDR: Chain Drug Review
2K
~0%
Subscriber count is a platform estimate
Pricing
$5/mo
$50/yr annual option
$883
~200 est. paid subs
$442/mo – $1K/mo(±50%)
Daily
27.7 posts/week
58/100
Variable (~2.2d avg)
| Newsletter | Subscribers | Weekly Growth | Price | Platform |
|---|---|---|---|---|
| The Forgotten Side of Medicine | 343K | +0.3% | $7/mo | substack |
| Neuroscience & Wellness | 241K | +4.5% | $7.99/mo | substack |
| Nedra Nuggets | 151K | -0.3% | $6.99/mo | substack |
| COVID Intel - by William Makis (McGill Medicine) | 142K | N/A | $7.5/mo | substack |
| Month | Subscribers | Est. Revenue | Change |
|---|---|---|---|
| Feb 2026 | 2.4K | $1,037.92 | — |
| Apr 2026 | 2K | $883.33 | -14.9% |
| May 2026 | 2K | $883.33 | ~0% |
Platform Dependency
Uses ghost platform
Publishing Consistency
Variable publishing frequency
Key Person
Single-author publication — key-person dependency
Revenue Model
Active paid subscription tier
Subscriber threshold
2K subscribers — above the 2K category median for first paid tier
Has paid tier
Active paid subscription offering
Peer monetization
100% of 427 similar-size peers in Health have paid tiers
Pricing position
$5/mo vs $6/mo category median (921 newsletters)
| Date | Monthly | Annual |
|---|---|---|
| Mar 2026 | $5 | $50 |
Disclaimer: This report is generated automatically based on publicly available data and proprietary estimation models. Estimated subscriber counts are derived from engagement patterns and should be verified through direct disclosure. Revenue estimates are based on known pricing and estimated paid subscriber counts. This report is for informational purposes only and should not be the sole basis for investment decisions.
| Component | Score | Weight |
|---|---|---|
| Publishing Consistency | 8/100 | 10% |
| Unbiased Science | 124K | +0.4% | $5/mo | substack |